

"Express Mail" mailing label number EL018701613US

Date of Deposit April 12, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Queen Thomas  
Printed Name

*Queen Thomas*  
Signature

**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant : Suad Efendic )  
For : USE OF GLP-1 AND ANALOGS )  
IN THE TREATMENT OF MYOCARDIAL )  
INFARCTION )  
Docket No. : X-10822A )

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents  
Washington, D. C. 20231  
Sir:

This preliminary amendment accompanies a continuation application of allowed application no. 08/915,918.

Please make the following amendments:

**In the Specification**

Delete the first sentence of the specification which contains cross reference data.

Add the following section immediately prior to the heading "Background of the Invention":

**Cross Reference to Related Application**

This application claims the benefit of U.S. Provisional Application Serial Number 60/024,980, filed August 30, 1996 and U.S. Nonprovisional Application Serial Number 08/915,918,

filed August 21, 1997.

In the Claims

Please cancel all claims and add the following new claims.

22. A method of reducing the mortality and morbidity after myocardial infarction, comprising administering to a patient in need thereof, a pharmaceutical composition comprising a compound selected from the group consisting of GLP-1, GLP-1 analogs, and GLP-1 derivatives, a buffer, and a preservative at a dose effective to normalize blood glucose.
23. A method of reducing the mortality and morbidity after myocardial infarction, comprising administering to a patient in need thereof, a compound selected from the group consisting of GLP-1, GLP-1 analogs, and GLP-1 derivatives, wherein the administration occurs within the first 72 hours following a myocardial infarction.
24. A method of reducing the mortality and morbidity after myocardial infarction, comprising administering to a patient in need thereof, a GLP-1 derivative at a dose effective to normalize blood glucose.
25. The method of Claim 24, wherein the GLP-1 derivative is a GLP-1 analog having an acylated lysine  $\epsilon$ -amino group.
26. The method of Claim 22, wherein the compound is complexed with a divalent metal cation.
27. The method of Claim 22, wherein the preservative is selected from the group consisting of meta-cresol and phenol.

28. The method of Claim 22, wherein the compound is selected from the group consisting of Val<sup>8</sup>-GLP-1(7-37), Gly<sup>8</sup>-GLP-1(7-37), GLP-1(7-37), and GLP-1(7-36)NH<sub>2</sub>.
29. A method of reducing morbidity and mortality after myocardial infarction, comprising, administering to a patient in need thereof a compound that exerts insulinotropic activity by interacting with the same receptor, or receptors, with which GLP-1, GLP-1 analogs, and GLP-1 derivatives interact in exerting their insulinotropic activity at a dose effective to normalize blood glucose.
30. A method of reducing morbidity and mortality after myocardial infarction, comprising, administering to a patient in need thereof a compound that enhances insulin sensitivity by interacting with the same receptor, or receptors, with which GLP-1, GLP-1 analogs, and GLP-1 derivatives interact in enhancing insulin sensitivity at a dose effective to normalize blood glucose.


**Remarks**

Support for these claims can be found throughout the Specification. For example, GLP-1 analogs and derivatives are defined and exemplified on page 6 through 12. Buffers and preservatives are discussed on page 20, lines 10 through 22. Discussion of the acute phase of myocardial infarction and treatment thereof is discussed beginning on the bottom on page 21 through page 22, line 16. GLP-1 derivatives and acylation of ε-amino groups are discussed on page 7 lines 8 through 12. Discussion of GLP-1s complexed with divalent metal cations can be found on page 20, lines 3 through 9. The preservatives meta-cresol and phenol are discussed on page 20, lines 16 through 18. Specific compounds encompassed by Claim 28 are disclosed on page 10, lines 1 through 7. The biological activities of GLP-1 such as those specified in Claims 29 and 30 are discussed on page 4, lines 7 through 31. Further Claims

X-10822A  
Suad Efendic

29 and 30 correspond to originally filed Claims 12 and 13 in  
the parent application.

Respectfully submitted,



Mark J. Stewart, Ph.D.  
Attorney for Applicant  
Registration No. 43,936  
Phone: 317-276-0280

Eli Lilly and Company  
Patent Division/MJS  
Lilly Corporate Center  
Indianapolis, Indiana 46285

April 12, 2001